Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04332653
Other study ID # NIT-110
Secondary ID MK-3475-A60KEYNO
Status Active, not recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date June 10, 2020
Est. completion date March 31, 2025

Study information

Verified date March 2024
Source NeoImmuneTech
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purposes of Phase 1b of this study are to determine the following in participants with advanced solid tumors: - Safety and tolerability of NT-I7 in combination with pembrolizumab - Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) The main purpose of Phase 2a of this study is to assess the preliminary anti-tumor activity of NT-I7 in combination with pembrolizumab in participants with checkpoint inhibitor (CPI) treated and naïve relapsed and refractory (R/R) tumors. The main purpose of the Biomarker Cohort is to assess a potential correlation between tumor infiltrating lymphocytes (TILs) and clinical benefits in participants with CPI-naïve R/R ovarian cancer (OC).


Description:

This is a multicenter, open-label Phase 1b/2a study of NT-I7 in combination with pembrolizumab. The study consists of a dose escalation phase (Phase 1b) followed by a dose expansion phase (Phase 2a) and a Biomarker Cohort. The Phase 1b is designed to assess the safety and tolerability, including determination of the Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) of NT-I7. The main purpose of Phase 2a of this study is to assess the preliminary antitumor activity of NT-I7 in combination with pembrolizumab in participants with relapsed/refractory - checkpoint inhibitor (CPI)-treated Triple Negative Breast Cancer (TNBC), Non-small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC) - checkpoint inhibitor (CPI)-naïve Microsatellite Stable Colorectal Cancer (MSS-CRC), and Pancreatic Cancer (PC) The Biomarker Cohort is designed to assess the correlation between tumor infiltrating lymphocytes (TILs) and clinical benefits of NT-I7 in combination with pembrolizumab in participants with CPI naïve R/R Ovarian Cancer (OC).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 215
Est. completion date March 31, 2025
Est. primary completion date November 5, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: (Participants must meet all the following to be eligible) - Participants with histologically or cytologically confirmed advanced or metastatic solid tumors. - Have measurable disease per RECIST v1.1. - Participants enrolling in the Phase 1b, Arms I, IV, IVa, V, and Va of the Phase 2a, and the Biomarker Cohort OC must have biopsiable disease. - Female participants who are either postmenopausal for at least 1 year, are surgically sterile for at least 6 weeks; female participants of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or to use dual methods of contraception for the duration of study treatment and for 120 days after the last dose of study treatment (pembrolizumab and/or NT-I7). - Non-sterile male participants who are sexually active with female partners of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or to use highly effective method(s) of contraception for the duration of study treatment and for 120 days after the last dose of study treatment (pembrolizumab and/or NT-I7). - Meet the requirements for the intended stages and arms (disease specific inclusion criteria), as follows: Applicable to the Dose escalation phase (Phase 1b) only: (Biopsy Arm) - Relapsed/refractory advanced solid tumors. Applicable to the Dose expansion phase (Phase 2a) only: Anti-PD-1/anti-PD-L1 refractory criteria for CPI-treated TNBC, NSCLC, and SCLC - Has received at least 2 doses of an approved anti-PD-1/anti-PD-L1 monoclonal antibody (mAb). - Has demonstrated disease progression after anti-PD-1/anti-PD-L1. Specific to Arm I: CPI-treated R/R TNBC (Biopsy Arm) - Histopathologic or cytologic documented TNBC. - Received one or more prior therapies for TNBC in the advanced or metastatic setting, and prior treatment (for advanced, metastatic or (neo) adjuvant). Specific to Arm II: CPI-treated R/R NSCLC - Had prior treatment with CPI. Participants with estimated glomerular filtration rate (EGFR), BRAF, or c-ros oncogene 1(ROS1) mutations or anaplastic lymphoma kinase (ALK) translocations are required to have received prior therapy with the appropriate tyrosine kinase inhibitor (TKI). Specific to Arm III: CPI-treated R/R SCLC - Recurrent extensive-stage SCLC; Received prior CPI therapy. Specific to Arm IV and IVa: CPI-naïve R/R MSS-CRC (Biopsy Arm) - MSS-CRC (categorized as MSS by immunohistochemistry(IHC) or polymerase chain reaction (PCR). - Previously treated with standard therapies, which must include fluoropyrimidine, oxaliplatin, and irinotecan; participants treated with CPI are not eligible. Specific to Arm V and Va: CPI-naïve R/R Pancreatic Cancer (Biopsy Arm) - Have documented radiographic progression to or documented in tolerance of first line systemic chemotherapy which included either gemcitabine or Fluorouracil (5-FU)-based regimen (including capecitabine); participants treated previously with CPI are not eligible. Specific to Biomarker Cohort: CPI-naïve R/R Ovarian Cancer - Up to 5 prior lines of treatment, including platinum-based treatment(s); participants treated previously with CPIs are not eligible. - Willing to provide pre- and on-treatment tumor biopsies. Exclusion Criteria: - Pregnant, lactating or breastfeeding. - Receiving chemotherapy or any anti-cancer therapy (approved or investigational) with half-life <1 week within 30 days or 5 half-lives. - Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate if stable. - Participants who have received treatment with systemic immunosuppressive medications. - Has a history of non-infectious pneumonitis that required steroids or current pneumonitis. - Has had an allogenic tissue/solid organ transplant or bone marrow transplant. - Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX-40, CD137) and was discontinued from that treatment due to a Grade 3 or higher Immune related adverse event (irAE).

Study Design


Intervention

Drug:
NT-I7
Administered by intramuscular (IM) injection
pembrolizumab (KEYTRUDA®)
Administered by intravenous (IV) injection

Locations

Country Name City State
United States Mary Crowley Cancer Research Dallas Texas
United States Barbara Ann Karmanos Cancer Institute Detroit Michigan
United States Duke University Medical Center Durham North Carolina
United States MD Anderson Cancer Center Houston Texas
United States Sarah Cannon Research Institute Nashville Tennessee
United States Fox Chase Cancer Center Philadelphia Pennsylvania
United States Washington University School of Medicine in St. Louis Saint Louis Missouri
United States Moffit Cancer Center Tampa Florida

Sponsors (2)

Lead Sponsor Collaborator
NeoImmuneTech Merck Sharp & Dohme LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phase 1b: Safety and Tolerability of NT-I7 in Combination With Pembrolizumab to Determine the Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) of NT-I7 Incidence, nature and severity of Adverse Events (AEs) graded according to NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0
Incidence and nature of Dose-Limiting Toxicities (DLTs)
Up to 2 years
Primary Phase 1b: Safety and Tolerability of NT-I7 in Combination With Pembrolizumab to Determine the Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) of NT-I7 Statistical correlation of dose levels with safety and efficacy parameters. Up to 2 years
Primary Phase 2a: Preliminary Assessment of the Objective Response Rate (ORR) of NT-I7 in Combination with Pembrolizumab Up to 2 years
Primary Biomarker Cohort: Number of Tumor-Infiltrating Lymphocytes (TILs) Up to 2 years
Primary Biomarker Cohort: Distribution of Tumor-Infiltrating Lymphocytes (TILs) TILs in tumor biopsy samples will be identified using a multi-spectral Immunofluorescence (IF) assay. Up to 2 years
Primary Biomarker Cohort: Phenotype of Tumor-Infiltrating Lymphocytes (TILs) TILs in tumor biopsy samples will be identified using a multi-spectral Immunofluorescence (IF) assay. Up to 2 years
Secondary Duration of Objective Response (DOR) Up to 2 years
Secondary Disease Control Rate (DCR) Up to 2 years
Secondary Progression Free Survival (PFS) Up to 2 years
Secondary Overall Survival (OS) Up to 2 years
Secondary Number of Participants Who Experience an Increase in Anti-Drug Antibodies (ADAs) to NT-I7 Up to 2 years
Secondary Biomarker Cohort: Objective Response Rate (ORR) Up to 2 years
Secondary Incidence, Nature, and Severity of Adverse Events (AEs) graded according to National Cancer Institute Common Terminologies Criteria for Adverse Events (NCI CTCAE) v5.0 Up to 2 years
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2